GlobeNewsWire
27 Jul 2026, 17:53 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
The FDA stated that Capricor Therapeutics' stem cell treatment for Duchenne muscular dystrophy failed to meet Phase 3 trial objectives. — Failure to meet primary endpoints in a Phase 3 trial for a core product is a critical negative catalyst for biotech valuations and regulatory approval prospects.
-0.90Holzer & Holzer, LLC is investigating whether Capricor Therapeutics complied with federal securities laws following claims that the company misrepresented trial results. — The threat of securities litigation and potential fraud allegations creates additional legal risk and corporate governance concerns.
-0.40Which stocks this story touches
FDA reported a Phase 3 trial failure and the company is under investigation for potential securities law violations.
Continue reading
6 related stories
Search tags
The company is facing a shareholder class action lawsuit.
The company is facing a shareholder class action lawsuit alleging overstated claims.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
2h ago
